Cardiol Therapeutics (CRDL) Total Current Liabilities (2020 - 2026)

Cardiol Therapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 3.79% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 3.79% YoY), and the FY2025 full-year result was $4.1 million, down 19.19% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $5.2 million, up from $4.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $8.9 million in Q2 2022, with the low at $2.4 million in Q3 2025.
• Historically, Total Current Liabilities has averaged $6.1 million across 5 years, with a median of $6.0 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 274.35% — and 2025, when it sank 53.11%.
• Cardiol Therapeutics' Total Current Liabilities stood at $7.2 million in 2022, then slipped by 15.64% to $6.1 million in 2023, then slipped by 17.65% to $5.0 million in 2024, then retreated by 19.19% to $4.1 million in 2025, then climbed by 28.15% to $5.2 million in 2026.
• The last three Total Current Liabilities figures came in at $5.2 million (Q1 2026), $4.1 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.